Project Details
Description
A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in subjects with clinical recent-onset Type 1 Diabetes Mellitus (T1D).
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/18 → 7/31/22 |
Funding
- INTREXON CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.